The Celgene’s anticancer drug ‘Revlimid’ has the lowest margin, which created more financial damages to sell

While the Korea Pharmaceutical Distribution Association is fighting a margin war with pharmaceutical companies, another low margin product has become an issue in the industry.

According to the distribution industry, Celgene provides a 3% margin and the 4-month payment condition on wholesale direct dealings of the relapsed and refractory multiple myeloma targeted agent ‘Revlimid’.

The pharmace...